What's Happening?
CicadaBio, a biotechnology company, has announced new preclinical data for its investigational GLP-1/anti-ActRII dual-pathway fusion protein, CC-18, during an oral presentation at the American Diabetes Association (ADA) Scientific Sessions 2026. The data revealed
significant weight reduction, preservation of lean mass, and reduced weight regain following treatment discontinuation. CC-18 is designed to address obesity by combining GLP-1 receptor activation with ActRII pathway blockade, aiming to reduce excess fat while preserving or increasing lean mass. The findings showed that in diet-induced obesity mouse models, CC-18 achieved greater weight reduction than semaglutide, with a 58% lower weight regain post-treatment. In non-human primate studies, the treatment demonstrated sustained weight reduction and favorable body composition changes, supporting the potential for extended dosing intervals.
Why It's Important?
The development of CC-18 is significant as it addresses a critical challenge in obesity treatment: achieving weight loss while preserving muscle mass. Current GLP-1-based therapies often result in a reduction of lean body mass, which is crucial for metabolic health and long-term weight maintenance. By focusing on high-quality weight loss, CicadaBio's approach could redefine obesity treatment, offering a solution that not only reduces weight but also improves body composition. This advancement could have substantial implications for the healthcare industry, potentially leading to more effective obesity management strategies and improved patient outcomes.
What's Next?
CC-18 is advancing in clinical development, with support from Lilly’s Catalyze360 initiative, which aids in clinical proof-of-concept activities. The next steps involve further clinical trials to validate the preclinical findings and assess the treatment's efficacy and safety in humans. If successful, CC-18 could become a leading therapy in obesity treatment, influencing healthcare policies and practices. Stakeholders, including healthcare providers and patients, will be closely monitoring the progress of these trials, as the results could impact treatment protocols and healthcare costs associated with obesity management.
